Experience
Eli Lilly and Company
Wockhardt Ltd.
Represented Eli Lilly in Hatch-Waxman patent infringement litigations against several ANDA filers seeking FDA approval to market generic versions of Eli Lilly's Cymbalta®. The S.D. Indiana entered judgment before trial in favor of Eli Lilly and against all the ANDA filers on all issues, resulting in orders and judgment maintaining Cymbalta's® market exclusivity through the end of its patent life.
Eli Lilly and Company v. Wockhardt Ltd., 1:08-cv-01547, S.D. Ind., Judges Baker, Lawrence, Pratt
Eli Lilly and Company v. Sicor Pharmaceuticals, Inc.
Eli Lilly and Company
Eli Lilly and Co. v. Apotex Inc.
Eli Lilly and Company
Eli Lilly and Company v. Teva Pharmaceuticals USA, Inc.
Eli Lilly and Company
Eli Lilly and Company v. Perrigo Co.
Eli Lilly and Company
Sun Pharmaceutical Inds. v. Eli Lilly and Co.
Eli Lilly and Company
Finnegan represented Eli Lilly on first genetically engineered biologic in the United States
Eli Lilly and Company
Eli Lilly and Co. wins challenge to patents covering its osteoporosis drug, Evista®
Eli Lilly and Company
Eli Lilly and Company
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.